City Therapeutics, Inc. (CTY) Stock
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
About City Therapeutics, Inc.
City Therapeutics, Inc. is headquartered in US.
City Therapeutics, Inc. (CTY) stock trades at $20.77 with a market capitalization of $201.93M. The stock is valued at price-to-book of 0.02, price-to-sales of 0.03. Over the past 52 weeks the stock has ranged between $20.27 and $23.88, and currently trades 13.0% below its 52-week high.
On profitability, City Therapeutics, Inc. generates a return on equity (ROE) of 18.28%, above the typical market range of roughly 12-15%, return on capital employed of 16.40%, an operating margin of 35.36%, a net profit margin of 22.40%.
City Therapeutics, Inc. by the numbers, 2010–2019
Between 2010 and 2019 City Therapeutics, Inc. reported revenue of $9.3B rising to $8.2B, a change of -12.0% across 10 years. Compounded, revenue has grown -1.6% a year over five years, -2.9% over three, -4.0% over the last twelve months. Net profit rose to $1.8B.
Operating margin went from 26.8% in 2010 to 35.4% in 2019, a gain of 8.6 percentage points. The most recent net margin is 22.40%. On a trailing twelve-month basis to Jun '20, revenue is $6.5B and net profit $1.8B.
Borrowings fell from $7.2B to $6.0B, cash on hand is $5.0M, cash from operations was $3.3B in the latest year, positive in 10 of the last 10.
Return on equity has averaged 15.4% over five years, and was 18.1% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
City Therapeutics, Inc. (CTY) — frequently asked questions
What is City Therapeutics, Inc. (CTY) stock price today?
City Therapeutics, Inc. (CTY) is currently trading at $20.77, up 0% today.
What is CTY return on equity (ROE)?
City Therapeutics, Inc.'s return on equity (ROE) is 18.28%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.
What is City Therapeutics, Inc.'s market cap?
City Therapeutics, Inc. has a market capitalization of $201.93M.
Does CTY pay a dividend?
City Therapeutics, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does CTY carry?
City Therapeutics, Inc. has a debt-to-equity ratio of 0.59. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is CTY's profit margin?
City Therapeutics, Inc. reports a net profit margin of 22.40% — the share of revenue left after every cost, including tax and interest.
What sector is CTY in?
City Therapeutics, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is CTY listed on?
City Therapeutics, Inc. trades on NASDAQ under the ticker CTY.
What is CTY's 52-week range?
Over the last year City Therapeutics, Inc. has traded between $20.27 and $23.88.
Related Healthcare Stocks
Popular Stocks
Screens CTY currently matches
On the figures above, City Therapeutics, Inc. passes the filters for 1 of our ready-made screens, among them Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.